We are live on ! Find out more
CCM

Camber Capital Management Portfolio holdings

AUM $1.07B
1-Year Est. Return 8.19%
This Fund
S&P 500
This Quarter Est. Return
+8.92%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$4.08B
AUM Growth
+$157M
Cap. Flow
-$183M
Cap. Flow %
-4.49%
Top 10 Hldgs %
70.38%
Holding
43
New
5
Increased
7
Reduced
8
Closed
7

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$93.7M
2
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$58.2M
3
DNLI icon
Denali Therapeutics
DNLI
+$28.2M
4
QGEN icon
Qiagen
QGEN
+$27.2M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$22.4M

Top Sells

Rank Stock Value
1
THC icon
Tenet Healthcare
THC
+$166M
2
UHS icon
Universal Health Services
UHS
+$102M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$43.8M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$43M
5
QDEL icon
QuidelOrtho
QDEL
+$29.5M

Sector Composition

Rank Sector Weight
1 Healthcare 67.95%
2 Consumer Staples 1.12%
3 Consumer Discretionary 0.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BKDT
26
DELISTED
Brookdale Senior Living Inc. 7.00% Tangible Equity Units
BKDT
$22.7M 0.56%
250,000
– –
REPL icon
27
Replimune Group
REPL
$1.01B
$22.5M 0.55%
2,750,000
+1,750,000
+175% +$14.4M
BMRN icon
28
BioMarin Pharmaceuticals
BMRN
$12.3B
$21.8M 0.54%
+250,000
New +$22.4M
PTON icon
29
Peloton Interactive
PTON
$2.46B
$19.3M 0.47%
4,500,000
– –
INGN icon
30
Inogen
INGN
$164M
$16.1M 0.4%
2,000,000
– –
SKIN icon
31
SkinHealth Systems
SKIN
$85.7M
$15.5M 0.38%
3,500,000
– –
BCYC
32
Bicycle Therapeutics
BCYC
$292M
$11.2M 0.27%
450,000
– –
TBPH icon
33
Theravance Biopharma
TBPH
$877M
$8.97M 0.22%
+1,000,000
New +$9.27M
PBYI icon
34
Puma Biotechnology
PBYI
$454M
$8.74M 0.21%
1,650,000
-1,155,000
-41% -$6.22M
CVAC
35
DELISTED
CureVac
CVAC
$5.3M 0.13%
1,750,000
– –
GMAB icon
36
Genmab
GMAB
$19.2B
$1.5M 0.04%
+50,000
New +$1.47M
ASND icon
37
Ascendis Pharma A/S
ASND
$16.8B
– –
-165,000
Closed -$20.8M
HRMY icon
38
Harmony Biosciences
HRMY
$2.24B
– –
-750,000
Closed -$24.2M
IONS icon
39
Ionis Pharmaceuticals
IONS
$9.4B
– –
-865,000
Closed -$43.8M
MRNA icon
40
Moderna
MRNA
$23.6B
– –
-250,000
Closed -$24.9M
QDEL icon
41
QuidelOrtho
QDEL
$838M
– –
-400,000
Closed -$29.5M
RARE icon
42
Ultragenyx Pharmaceutical
RARE
$2.55B
– –
-900,000
Closed -$43M
SLDB icon
43
Solid Biosciences
SLDB
$826M
– –
-1,418,439
Closed -$8.71M
1
2

Similar funds

PP
PrairieView Partners St. Paul, Minnesota $1.03B AUM 11.4% 1-Year Est. Return
SAF
Smith Anglin Financial Dallas, Texas $1.1B AUM 14.08% 1-Year Est. Return
NRD
Nebula Research & Development New York $1.17B AUM 15.19% 1-Year Est. Return
FC
Forte Capital Rochester, New York $930M AUM 24.11% 1-Year Est. Return
GIM
Grassi Investment Management Santa Clara, California $1.26B AUM 23.4% 1-Year Est. Return
SC
Savoie Capital Chicago, Illinois $805M AUM 19.48% 1-Year Est. Return
BWA
Bordeaux Wealth Advisors Menlo Park, California $781M AUM 26.55% 1-Year Est. Return
CCP
Camelot Capital Partners Laguna Beach, California $686M AUM 163.55% 1-Year Est. Return

Camber Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, Camber Capital Management held 43 positions worth $4.08B, up 4% from $3.92B the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Camber Capital Management withdrew a net $183M in Q1 2024, closing 7 positions and reducing 8 holdings. Its most notable exit was Ionis Pharmaceuticals, an estimated $43.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets, down from 71% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

Against the trend, Camber Capital Management opened a new position in Biogen worth $86.3M.

  • Camber Capital Management's largest Q1 2024 buy was Biogen: 400,000 shares worth $86.3M.
  • Camber Capital Management added most to Jazz Pharmaceuticals in Q1 2024, an estimated $58.2M increase.
  • Camber Capital Management's biggest Q1 2024 reduction was Tenet Healthcare, cutting an estimated $166M.
  • Camber Capital Management fully exited Ionis Pharmaceuticals in Q1 2024, selling an estimated $43.8M.
  • Camber Capital Management's ten largest holdings make up 70% of its $4.08B portfolio in Q1 2024.
  • Camber Capital Management opened 5 new positions and closed 7 in Q1 2024.
  • Camber Capital Management's portfolio value rose 4% quarter-over-quarter to $4.08B.

Based on Camber Capital Management's 13F filing for Q1 2024, filed 15 May 2024.